ChimeriVax-Dengue: Phase IIb started

sanofi's sanofi pasteur S.A. vaccines unit began a Taiwanese Phase IIb trial (Study 209) to evaluate subcutaneous ChimeriVax-Dengue vaccine in 4,000 healthy children ages 4-11. The vaccine uses Chime...